ArticleFrontiers in neurology
The EP-VRD2 for endovascular treatment of ophthalmic segment aneurysms: wall apposition and long-term study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The Enterprise Vascular Reconstruction Devices 2 (EP-VRD2) are designed to improve apposition to curved vessel walls. This study aimed to evaluate the wall apposition (WA) and long-term safety and effectiveness of EP-VRD2 for treating ophthalmic segment aneurysms (OSAs). Materials and methods: Dyna CT angiography (CTA) was used to evaluate WA, while digital subtraction angiography (DSA) and the modified Rankin score (mRS) were utilized for imaging and outcome follow-up, respectively. The minimum follow-up was 12 months. Results: A total of 104 OSAs treated with EP-VRD2 were collected. The complication rate was 3.84%, all due to thromboembolic events. Immediate angiography revealed Raymond-Roy occlusion classification (RROC) I in 73.08% of cases, II in 23.08%, and III in 3.84%. DSA follow-up of 90 OSAs over an average of 19.91 ± 7.16 months showed a complete occlusion rate of 95.56%. Clinical follow-up averaged 22.15 ± 9.26 months, with mRS ranging from 0 to 2. Crescent signs, indicating incomplete stent apposition (ISA), were observed in 11.54% of cases. Curvature radius (CR) and artery angle (AA) were significantly different between the complete apposition and ISA groups, with cut-off values identified at 44° and 3.58 mm. Conclusion: EP-VRD2 stents are safe and effective for long-term treatment of OSAs, significantly improving WA in curved vessels. However, ISA remains in sharp ICA siphon bends, particularly with an AA < 44° or CR < 3.58 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.